Closing Remarks

Dr. Shoemaker concluded the session by reviewing the topline themes from each of the speakers’ presentation, and summarized their collective relevance in driving future developments of next-generation cellular immunotherapies in the fight against cancer.

iPSC Derived CAR-Ts: Targeting Cancer with an Engineered, iPSC-Derived T Cell

Dr. Sadelain presented an overview of chimeric antigen receptor (CAR) and T cell receptor-modified T cell therapeutic strategies, including a history on the evolution of CAR-based strategies over the past two decades. He highlighted the clinical promise of this therapeutic approach, reviewed the challenges and limitations of current autologous approaches, and described the therapeutic advantages and potential strategies for generating “off-the-shelf” iPSC-derived T-cell therapies.

iPSC Derived NKs: Targeting Cancer with an Engineered, iPSC-Derived NK Cell

Dr. Kaufman presented the features and advantages of iPSC-derived NK cells versus NK cells derived from alternative sources. He also demonstrates the ability of these cells to eliminate both liquid and solid tumors without causing Graft Versus Host Disease (GVHD), and reviewed approaches for enhancing the potency of NK cells against tumors through genetic engineering of various targeting modalities.

Harnessing Hematopoiesis: Creating the Ideal Platform for Large-Scale Expansion of iPSC-Derived, Engineered Hematopoietic Cells

Dr. Valamehr presented Fate Therapeutics’ proprietary iPSC platform, which is designed for the consistent and scalable generation of iPSCs for off-the-shelf therapeutic use. He also reviewed Fate’s proprietary technology for the highly efficient differentiation of genetically-engineered iPSCs into cells of the hematopoietic lineage, including Natural Killer (NK) and T cell-based immunotherapy product candidates.